 Prolonged survival patients beta-thalassemia major deferoxamine survival patients beta-thalassemia major management hypertransfusion chelation deferoxamine longevity Kaplan-Meier product-limit method Group patients low-transfusion regimen pretransfusion level gm/dl chelation median age survival years years group subjects hypertransfusion pretransfusion level gm/dl chelation deferoxamine mg/kg day patients hypertransfusion deferoxamine data ratio total milligrams transfusional iron cumulative grams deferoxamine patients total iron burden gm/kg ratio patients poor compliance chelation late start therapy inability enough deferoxamine death Death arrhythmia therapy cardiac failure iron-loaded survivors ratio arrhythmia cardiac failure treatment deferoxamine amounts proportional burden delayed cardiac complications improved longevity